Known targets — ChEMBL curated mechanism
PPARDPTGS1PTGS2dacAdacBdacCftsImrcAmrcBmrdA
The experimentally established mechanism targets of Lysine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GSR | P00390 | 2/20 | 0.80 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.72 |
| ▸ | GRM8 | O00222 | 1/20 | 0.72 |
| ▸ | GRM6 | O15303 | 1/20 | 0.72 |
| ▸ | GRIN2D | O15399 | 1/20 | 0.72 |
| ▸ | GRIN3B | O60391 | 1/20 | 0.72 |
| ▸ | GRIK1 | P39086 | 1/20 | 0.72 |
| ▸ | GRM5 | P41594 | 1/20 | 0.72 |
| ▸ | GRIA1 | P42261 | 1/20 | 0.72 |
| ▸ | GRIA2 | P42262 | 1/20 | 0.72 |
| ▸ | GRIA3 | P42263 | 1/20 | 0.72 |
| ▸ | SLC1A3 | P43003 | 1/20 | 0.72 |
| ▸ | SLC1A2 | P43004 | 1/20 | 0.72 |
| ▸ | SLC1A1 | P43005 | 1/20 | 0.72 |
| ▸ | GRIA4 | P48058 | 1/20 | 0.72 |
| ▸ | GRIN1 | Q05586 | 1/20 | 0.72 |
| ▸ | GRIN2A | Q12879 | 1/20 | 0.72 |
| ▸ | GRIK2 | Q13002 | 1/20 | 0.72 |
| ▸ | GRIK3 | Q13003 | 1/20 | 0.72 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.72 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Lysine SCHEMBL8000337 | 1.00 | GSR (0.80) | GSRCYP1A2GRM8GRM6GRIN2D | |
| D-Glutamate SCHEMBL27400214 | 1.00 | GSR (0.80) | GSRCYP1A2GRM8GRM6GRIN2D | |
| Lysine SCHEMBL7258645 | 1.00 | GSR (0.80) | GSRCYP1A2GRM8GRM6GRIN2D | |
| Lysine SCHEMBL890044 | 1.00 | GSR (0.80) | GSRCYP1A2GRM8GRM6GRIN2D | |
| D-Glutamate SCHEMBL1079951 | 1.00 | GSR (0.80) | GSRCYP1A2GRM8GRM6GRIN2D | |
| Lysine SCHEMBL8000334 | 1.00 | GSR (0.80) | GSRCYP1A2GRM8GRM6GRIN2D | |
| D-Glutamate SCHEMBL2415481 | 1.00 | GSR (0.80) | GSRCYP1A2GRM8GRM6GRIN2D | |
| Lysine SCHEMBL205003 | 1.00 | GSR (0.80) | GSRCYP1A2GRM8GRM6GRIN2D | |
| D-Glutamate SCHEMBL21796040 | 1.00 | GSR (0.80) | GSRCYP1A2GRM8GRM6GRIN2D | |
| Lysine SCHEMBL6034319 | 0.98 | GSR (0.77) | GSRCYP1A2GRM8GRM6GRIN2D |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 67 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240052034-A1 | MULTI-PARATOPIC ANTI-PD-1 ANTIBODIES AND USES THEREOF | Pandion Operations, Inc. (US) | 2024-02-15 | — | — | US | claimed |
| EP-4233892-A2 | STABLE ANTI-IFNAR1 FORMULATION | Astrazeneca AB (SE) | 2023-08-30 | — | — | EP | claimed |
| CN-116368155-A | Multi-paratope anti-PD-1 antibodies and uses thereof | 潘迪恩运营公司 | 2023-06-30 | — | — | CN | claimed |
| EP-4200324-A1 | MULTI-PARATOPIC ANTI-PD-1 ANTIBODIES AND USES THEREOF | Pandion Operations, Inc. (US) | 2023-06-28 | — | — | EP | claimed |
| EP-3769781-B1 | STABLE ANTI-IFNAR1 FORMULATION | ASTRAZENECA AB (SE) | 2023-04-19 | — | — | EP | claimed |
| EP-3769781-A1 | STABLE ANTI-IFNAR1 FORMULATION | Astrazeneca AB (SE) | 2021-01-27 | — | — | EP | claimed |
| EP-3337502-A1 | STABLE ANTI-IFNAR1 FORMULATION | Astrazeneca AB (SE) | 2018-06-27 | — | — | EP | claimed |
| WO-2017031288-A1 | STABLE ANTI-IFNAR1 FORMULATION | MEDIMMUNE, LLC (US) | 2017-02-23 | — | — | WO | claimed |
| CN-122006677-A | Nano magnetic bead based on polyamino acid material, preparation method thereof and application thereof in early cancer screening | 中国科学院长春应用化学研究所 | 2026-05-12 | — | — | CN | disclosed |
| US-12474298-B2 | Isoelectric focusing sample matrix | BRISTOL-MYERS SQUIBB COMPANY (US) | 2025-11-18 | — | — | US | disclosed |
| US-12326455-B2 | Devices, methods and kits for sample characterization | INTABIO, INC. (US) | 2025-06-10 | — | — | US | disclosed |
| EP-4097208-B1 | ISOELECTRIC FOCUSING SAMPLE MATRIX | BRISTOL MYERS SQUIBB CO (US) | 2025-04-09 | — | — | EP | disclosed |
| CN-118667894-A | Process for preparing 5-aminopentanamide and 5-aminopentanoic acid | 广安摩珈生物科技有限公司 | 2024-09-20 | — | — | CN | disclosed |
| CN-118475336-A | Personal care compositions based on amino acid surfactants | 宝洁公司 | 2024-08-09 | — | — | CN | disclosed |
| WO-2007124440-A2 | NOVEL POLYMORPHISM IN BOVINE PRION PROTEIN GENE SEQUENCE | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY OF AGRICULTURE (US) | 2007-11-01 | — | — | WO | disclosed |
| WO-2007012138-A1 | IDENTIFICATION OF GENES AND THEIR PRODUCTS WHICH PROMOTE HYBRID VIGOUR OR HYBRID DEBILITY AND USES THEREOF | HYBRID BIOSCIENCES PTY LTD (AU) | 2007-02-01 | — | — | WO | disclosed |
| WO-2006114799-A1 | SYNTHETIC PEPTIDES FOR THE DIAGNOSIS AND THERAPY OF BERILLIUM GRANULOMATOUS DISEASE | UNIVERSITA' DEGLI STUDI DI ROMA 'TOR VERGATA' (IT) | 2006-11-02 | — | — | WO | disclosed |
| EP-1713931-A1 | METHOD OF IDENTIFYING GENES WHICH PROMOTE HYBRID VIGOUR AND HYBRID DEBILITY AND USES THEREOF | Hybrid Biosciences Pty Ltd (AU) | 2006-10-25 | — | — | EP | disclosed |
| WO-2005075668-A1 | METHOD OF IDENTIFYING GENES WHICH PROMOTE HYBRID VIGOUR AND HYBRID DEBILITY AND USES THEREOF | HYBRID BIOSCIENCES PTY LTD (AU) | 2005-08-18 | — | — | WO | disclosed |
| CN-1261791-A | Targeted liposomal constructs for diagnostic and therapeutic uses | SDG INC (US) | 2000-08-02 | — | — | CN | disclosed |